Merck & Co. has yet to report first-quarter earnings, so industry watchers still don’t know exactly how much market share the company’s new hep C combo treatment, Zepatier, has scored since winning approval in late January. But so far, comments from its competitors suggest it’s doing pretty well for itself.
03 May 2016 | Fierce Pharma
Seven health-insurance companies in New York will change their criteria for covering costly drugs that cure chronic hepatitis C under the terms of agreements with the office of State Attorney General Eric Schneiderman.
26 April 2016 | Wall Street Journal
The model suggested that over 20 years, enrolling a quarter of HIV uninfected injection drug users in a PrEP + screening + ART program would be the optimal approach for reducing HIV infection. However, at current drug prices this approach would cost the U.S. an additional $44 billion, which is equivalent to annually spending 10 percent of the current federal budget for domestic HIV/AIDS on PrEP for people who inject drugs.
26 April 2016 | Medical Xpress
In Kenya an ambitious new target to increase national funding of HIV research sees the government expecting to raise about USD109 million from local sources over the next five years.
18 April 2016 | Key Correspondents
The World Hepatitis Alliance welcomes the announcement of a new programme initiated by the Clinton Health Access Initiative, Inc. (CHAI) and AmeriCares that aims to treat 10,000 co-infected HIV and hepatitis C patients in Africa and Asia with new hepatitis C treatment Daklinza (daclatasvir).
14 April 2016 | World Hepatitis Alliance
Calls for low and middle income countries to contribute an additional 6.1 billion dollars to the global HIV response by 2020 could see some vulnerable groups left behind, said HIV activists meeting at the United Nations last week.
12 April 2016 | Inter Press Service
The agency’s new projections about what is needed to end the AIDS epidemic make completely unrealistic and unreasonable expectations about what low- and middle-income countries can and will pay — suggesting a dangerous donor strategy in the face of high stakes. Low- and middle-income countries can and must pay more — leading AIDS activists from high burden countries have long demanded this and are, in many cases, winning increases. But UNAIDS itself predicts that if the money needed to close this gap does not materialize by 2020, we will not hit the fast track goals.
06 April 2016 | HealthGAP
India is firing dozens of foreign-funded health experts working inside the government, seen as part of a broader clampdown to reduce the influence of non-government organizations (NGOs) on policy. Of the nearly 140 people who run India's HIV/AIDS program, 112 are consultants seconded from foreign organizations.
06 April 2016 | Reuters
Greater investment in civil society and community-based service delivery is critical to the Fast-Track approach. Outreach to key populations in low- and middle-income countries should grow to about 7.2% of total investments by 2020, and the estimated resource needs for community-based delivery of antiretroviral therapy should grow to about 3.8% of total investment.
06 April 2016 | UNAIDS
Ahead of the United Nations General Assembly High-Level Meeting on Ending AIDS, UNAIDS announced new investment needs to Fast-Track the AIDS response. The projected need of US$ 26.2 billion in 2020 is down from a previous estimate of US$ 30 billion. New findings suggest that the world can reach ambitious Fast-Track targets for preventing new HIV infections, AIDS-related deaths and discrimination with fewer resources.
04 April 2016 | UNAIDS